Long-term Clinical Outcomes in Patients with Refractory Uveitis Associated with Behçet Disease Treated with Infliximab

References

• International Study Group for Behçet's Disease. Criteria for diagnosis of Behçet's disease. Lancet. 1990;335:1078–1080
   PubMed Web of Science ®Google Scholar
• Sakane T, Takeno M. New approaches to Behçet's disease. Exp Opin Invest Drugs. 2000;9:1993–2005
   PubMed Web of Science ®Google Scholar
• Tugal-Tukun I, Onal S, Altan-Yaycioglu R, et al. Uveitis in Behçet's disease: an analysis of 880 patients. Am J Ophthalmol. 2004;138:373–380
   Google Scholar
• El-Asrar AM, Struyf S, Kangave D, et al. Cytokine profiles in aqueous humor of patients with different clinical entities of endogenous uveitis. Clin Immunol. 2011;139:177–184
   PubMed Web of Science ®Google Scholar
• El-Asrar AM, Al-Obeidan SS, Kangave D, et al. CXC chemokine expression profiles in aqueous humor of patients with different clinical entities of endogenous uveitis. Immunobiology. 2011;216:1004–1009
   PubMed Web of Science ®Google Scholar
• Mage JL, Dilsen N, Sanguedolce V, et al. Overproduction of monocyte derived tumor necrosis factor alpha, interleukin (IL) 6, IL-8 and increased neutrophil superoxide generation in Behçet's disease: a comparative study with familial Mediterranean fever and healthy subjects. J Rheumatol. 1993;20:1544–1549
   PubMed Web of Science ®Google Scholar
• Misumi M, Hagiwara E, Takeno M, et al. Cytokine production profile in patients with Behçet's disease treated with infliximab. Cytokine. 2003;24:210–218
   PubMed Web of Science ®Google Scholar
• Turan B, Gallati H, Erdi H, et al. Systemic levels of the T cell regulatory cytokines IL-10 and IL-12 in Behçet's disease: soluble TNFR-75 as a biological marker of disease activity. J Rheumatol. 1997;24:128–132
   PubMed Web of Science ®Google Scholar
• Evereklioglu C, Er H, Turkoz Y, et al. Serum levels of TNF-alpha, sIL-2R, IL-6, and IL-8 are increased and associated with elevated lipid peroxidation in patients with Behçet's disease. Mediators Inflamm. 2002;11:87–93
   PubMed Web of Science ®Google Scholar
• Bardak Y, Aridogan BC. The demonstration of serum interleukin 6–8, tumor necrosis factor-alpha, complement, and immunoglobulin levels in Behçet's disease with ocular involvement. Ocul Immunol Inflamm. 2004;12:53–58
   PubMed Web of Science ®Google Scholar
• Santos Lacomba M, Marcos Martin C, Gallardo Galera JM, et al. Aqueous humor and serum tumor necrosis factor-alpha in clinical uveitis. Ophthalmic Res. 2001;33:251–255
   PubMed Web of Science ®Google Scholar
• Greiner K, Murphy CC, Willermain F, et al. Anti-TNF α therapy modulates the phenotype of peripheral blood CD4+ T cells in patients with posterior segment intraocular inflammation. Invest Ophthalmol Vis Sci. 2004;45:170–176
   PubMed Web of Science ®Google Scholar
• Sfikakis PP, Kaklamanis PH, Elezoglou A, et al. Infliximab for recurrent sight-threatening ocular inflammation in Adamantiades-Behçet's disease. Ann Intern Med. 2004;140:404–406
   PubMed Web of Science ®Google Scholar
• Tugal-Tutkun I, Mudun A, Urgancioglu M, et al. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet's disease. Arthritis Rheum. 2005;52:2478–2484
   PubMed Web of Science ®Google Scholar
• Ohno S, Makamura S, Hori S, et al. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behçet's disease with refractory uveoretinitis. J Rheumatol. 2004;31:1362–1368
   PubMed Web of Science ®Google Scholar
• Lantbier N, Parc C, Scavennec R, et al. Infliximab in the treatment of posterior uveitis in Behçet's disease: long term follow-up in four patients. Press Med. 2005;34:916–918
   PubMedGoogle Scholar
• Wechsler B, Sable-Fourtassou R, Bodaghi B, et al. Infliximab in refractory uveitis due to Behçet's disease. Clin Exp Rheumatol. 2004;22:S14–S16
   PubMed Web of Science ®Google Scholar
• Abu El-Asrar AM, Abboud EB, Aldibhi H, et al. Long-term safety and efficacy of infliximab therapy in refractory uveitis due to Behçet's disease. Int Ophthalmol. 2005;26:83–92
   PubMedGoogle Scholar
• Niccoli L, Nannini C, Benucci M, et al. Long-term efficacy of infliximab in refractory posterior uveitis of Behçet's disease: a 24-month follow-up study. Rheumatology (Oxford). 2007;46:1161–1164
   PubMed Web of Science ®Google Scholar
• Al-Rayes H, Al-Swailem R, Al-Balawi M, et al. Safety and efficacy of infliximab therapy in active Behçet's uveitis: an open-label trial. Rheumatol Int. 2008;29:53–57
   PubMed Web of Science ®Google Scholar
• Accorinti M, Pirraglia MP, Paroli MP, et al. Infliximab treatment for ocular and extraocular manifestations of Behçet's disease. Jpn J Ophthalmol. 2007;51:191–196
   PubMed Web of Science ®Google Scholar
• Keino H, Okada AA, Watanabe T, Taki W. Decreased ocular inflammatory attacks and background retinal and disc vascular leakage in patients with Behçet's disease on infliximab therapy. Br J Ophthalmol. 2011;95:1245–1250
   PubMed Web of Science ®Google Scholar
• Tabbara KF, Al-Hemidan AI. Infliximab effects compared to conventional therapy in the management of retinal vasculitis in Behçet's disease. Am J Ophthalmol. 2008;146:845–850
   PubMed Web of Science ®Google Scholar
• Tognon S, Graziani G, Marcolongo R. Anti-TNF-alpha therapy in seven patients with Behçet's disease: advantages and controversial aspects. Ann N Y Acad Sci. 2007;1110:474–484
   PubMed Web of Science ®Google Scholar
• Takeuchi M, Asukata Y, Kawagoe T, et al. Infliximab monotherapy versus infliximab and colchicine combination therapy in patients with Behçet's disease. Ocul Immunol Inflamm 2012;20:193–197
   PubMed Web of Science ®Google Scholar
• Capella MJ, Foster CS. Long-term efficacy and safety of infliximab in the treatment of Behçet's disease. Ocul Immunol Inflamm. 2012;20:198–202
   PubMed Web of Science ®Google Scholar
• Okada AA, Goto H, Ohno S, Mochizuki M. Ocular Behçet's Disease Research Group of Japan. Multicenter study of infliximab for refractory uveoretinitis in Behçet's disease. Arch Ophthalmol. 2012;130:592–598
   PubMed Web of Science ®Google Scholar
• Yamada Y, Sugita S, Tanaka H, et al. Timing of recurrent uveitis in patients with Behcet's disease receiving infliximab treatment. Br J Ophthalmol. 2011;95:205–208
   PubMed Web of Science ®Google Scholar
• Sugita S, Yamada Y, Mochizuki M. Relationship between serum infliximab levels and acute uveitis attacks in patients with Behcet disease. Br J Ophthalmol. 2011;95:549–552
   PubMed Web of Science ®Google Scholar
• Sugita S, Yamada Y, Kaneko S, et al. Induction of regulatory T cells by infliximab in Behcet's disease. Invest Ophthalmol Vis Sci. 2011;52:476–484
   PubMed Web of Science ®Google Scholar
• Ozdal PC, Ortaç S, Taşkintuna I, Firat E. Posterior segment involvement in ocular Behçet's disease. Eur J Ophthalmol. 2002;12:424–431
   PubMed Web of Science ®Google Scholar
• Markomichelakis NN, Theodossiadis PG, Pantelia E, et al. Infliximab for chronic cycstoid macular edema associated with uveitis. Am J Ophthalmol. 2004;138:648–650
   PubMed Web of Science ®Google Scholar
• Noda E, Yamanishi S, Shiraishi A, Ohashi Y. Cataract surgery under infliximab therapy in a patient with Behçet's disease. J Ocul Pharmacol Ther. 2009;25:467–470
   PubMedGoogle Scholar
• Sakai T, Kanetaka A, Noro T, Tsuneoka H. Intraocular surgery in patients receiving infliximab therapy for Behçet disease. Jpn J Ophthalmol. 2010;54:360–361
   PubMedGoogle Scholar
• Nishida T, Shibuya E, Asukata Y, et al. Clinical course before and after cataract and glaucoma surgery under systemic infliximab therapy in patients with Behçet's disease. Case Rep Ophthalmol. 2011;2:189–192
   PubMedGoogle Scholar
• Elezoglou A, Kafasi N, Kaklamanis PH, et al. Infliximab treatment-induced formation of autoantibodies is common in Behçet's disease. Clin Exp Rheumatol. 2007;25:S65–S69
   Google Scholar
• Iwata D, Namba K, Mizuuchi K, et al. Correlation between elevation of serum antinuclear antibody titer and decreased therapeutic efficacy in the treatment of Behçet's disease with infliximab. Graefes Arch Clin Exp Ophthalmol. 2012;250:1081–1087
   PubMed Web of Science ®Google Scholar
• Adán A, Hernandez V, Ortiz S, et al. Effects of infliximab in the treatment of refractory posterior uveitis of Behçet's disease after withdrawal of infusions. Int Ophthalmol. 2010;30:577–581
   PubMedGoogle Scholar
• Quinn MA, Conaghan PG, O'Connor PJ, et al. Very early treatment with infliximab in addition to metrotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, pacebo-controlled trial. Arthritis Rheum. 2005;51:27–35
   Google Scholar
• van der Bijl AE, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, et al. Infliximab and methotrexate as induction therapy in patients with early rheumatoid arthritis. Arthritis Rheum. 2007;56:2129–2134
   PubMed Web of Science ®Google Scholar
• Caviglia R, Ribolsi M, Rizzi M, et al. Maintenance of remission with infliximab in inflammatory bowel disease: efficacy and safety long-term follow-up. World J Gastroenterol. 2007;13:5238–5244
   PubMed Web of Science ®Google Scholar
• Perra D, Alba MA, Callejas JL, et al. Adalimumab for the treatment of Behçet's disease: experience in 19 patients. Rheumatology (Oxford). 2012;51:1825–1831
   PubMed Web of Science ®Google Scholar
• Bawazeer A, Raffa LH, Nizamuddin SH. Clinical experience with adalimumab in the treatment of ocular Behçet's disease. Ocul Immunol Inflamm. 2010;18:226–232
   PubMed Web of Science ®Google Scholar
• Mushtaq B, Saeed T, Situnayake RD, Murray PI. Adalimumab for sight-threatening uveitis in Behçet's disease. Eye (Lond). 2007;21:824–825
   PubMed Web of Science ®Google Scholar
• Takase K, Ohno S, Ideguchi H, et al. Successful switching to adalimumab in an infliximab-allergic patient with severe Behçet's disease-related uveitis. Rheumatol Int. 2011;31:243–245
   PubMed Web of Science ®Google Scholar
• Olivieri I, Leccese P, D'Angelo S, et al. Efficacy of adalimumab in patients with Behçet's disease unsuccessfully treated with infliximab. Clin Exp Rheumatol. 2011;29:S54–S57
   PubMed Web of Science ®Google Scholar